Table 3. Endocrine-related adverse events according to ICI type.
| Primary thyroid dysfunction, n (%) | 14 (100) | |
| Anti-PD-1a | 11 (78.6) | |
| Anti-PDL-1b | 3 (21.4) | |
| Hypopituitarism, n (%) | 8 (100) | |
| Anti-PD-1a | 8 (100) | |
Abbreviations: ICI, immune checkpoint inhibitor; PD, programmed death; PD-L, programmed death ligand.
Anti-PD-1 treatment: nivolumab or pembrolizumab
Anti-PDL-1 treatment: atezolizumab or durvalumab